Review
Pharmacology & Pharmacy
Stephanos Vassilopoulos, Fadi Shehadeh, Markos Kalligeros, Quynh-Lam Tran, Fred Schiffman, Eleftherios Mylonakis
Summary: Patients with CLL/SLL who receive targeted therapies have a high cumulative incidence of severe infections, which is closely related to the mechanism of action of the used drug.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Hematology
Tanya Siddiqi, Jacob D. Soumerai, Kathleen A. Dorritie, Deborah M. Stephens, Peter A. Riedell, Jon Arnason, Thomas J. Kipps, Heidi H. Gillenwater, Lucy Gong, Lin Yang, Ken Ogasawara, Jerill Thorpe, William G. Wierda
Summary: Lisocabtagene maraleucel, an autologous CD19-directed CAR T-cell therapy, shows promising safety and efficacy in patients with relapsed/refractory CLL/SLL, providing a potential new treatment option for these patients who develop resistance to current therapies.
Article
Oncology
Anthony R. Mato, Matthew S. Davids, Jeff Sharman, Lindsey E. Roeker, Neil Kay, Arnon P. Kater, Kerry Rogers, Meghan C. Thompson, Joanna Rhodes, Andre Goy, Alan Skarbnik, Stephen J. Schuster, Constantine S. Tam, Toby A. Eyre, Susan O'Brien, Chadi Nabhan, Nicole Lamanna, Clare Sun, Mazyar Shadman, John M. Pagel, Chaitra Ujjani, Danielle Brander, Catherine C. Coombs, Nitin Jain, Chan Y. Cheah, Jennifer R. Brown, John F. Seymour, Jennifer A. Woyach
Summary: The management of chronic lymphocytic leukemia (CLL) has experienced significant changes with the incorporation of targeted therapies into clinical practice. However, patients are developing resistance or intolerance to multiple classes of drugs, particularly symptomatic patients previously treated with BTK inhibitors and venetoclax. This article defines the unmet needs in the modern treatment context and critically reviews the literature for PI3K inhibitors and chemoimmunotherapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Jennifer A. Woyach
Summary: MRD assessment in chronic lymphocytic leukemia (CLL) may help determine prognosis, but its predictive value varies in different therapeutic contexts. It is unclear whether an MRD-guided treatment strategy is superior to fixed-duration therapy, requiring further research for validation.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Letter
Hematology
Anthony R. Mato, Nilanjan Ghosh, Jeff P. Sharman, Danielle Brander, Meghan Gutierrez, Qing Huang, Linda H. Wu, Alex Young, Sandhya Upasani, Maoko Naganuma, Jacqueline C. Barrientos
Summary: The treatment landscape for CLL/SLL is evolving with the availability of new therapies, and questions remain about optimal treatment selection in the real-world setting. Prognostic biomarker testing and risk stratification are important for treatment decisions. This study provides insights into real-world prognostic testing rates, treatment selection, and treatment patterns for CLL/SLL patients. COVID-19 outcomes among these patients are also reported.
Article
Medicine, General & Internal
Kerry A. Rogers, Bruno Emond, Ameur M. Manceur, Frederic Kinkead, Marie-Helene Lafeuille, Patrick Lefebvre, Qing Huang
Summary: This study aimed to describe treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax in a US managed care population. Patients previously receiving ibrutinib had lower mean total all-cause and clinical event-related costs during their venetoclax line of therapy than those previously receiving non-ibrutinib therapy. Highest mean costs were observed during venetoclax initiation phase in this descriptive study.
CURRENT MEDICAL RESEARCH AND OPINION
(2021)
Article
Oncology
Jennifer R. Brown
Summary: In relapsed chronic lymphocytic leukemia, treatment choices depend on various factors such as risk profile, prior therapy, and patient comorbidities. Different drug options are suitable for different situations of patients, and close monitoring is needed for treatment when the disease progresses.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Review
Oncology
Patricia Bott, Ilske Oschlies, Andreas Radeloff, Maureen Loewenthal
Summary: EBV-positive mucocutaneous ulcer (EBV-MCU) is a rare lymphoproliferative B-cell disease that needs to be distinguished from head and neck squamous cell carcinoma by early biopsy. This study provides a review of the current literature and a recommendation for EBV-MCU management. A total of 181 cases were identified and summarized, and it was found that EBV-MCU is predominantly caused by immunosuppressive drug therapy. Most cases can achieve complete remission by reducing immunosuppressive therapy.
Article
Hematology
Radowan Elnair, Moataz Ellithi, Avyakta Kallam, Valerie Shostrom, Robert G. Bociek
Summary: Richter's transformation (RT) is a rare complication in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and is associated with a dismal outcome. Patients with RT have a median overall survival of only 10 months and advanced Ann Arbor stage (III/IV) and prior treatment for CLL are predictors of worse outcome. This study contributes to the existing literature by providing insights into the poor outcomes for patients with CLL/SLL and RT.
ANNALS OF HEMATOLOGY
(2021)
Article
Medicine, General & Internal
Bor-Sheng Ko, Li-Ju Chen, Huai-Hsuan Huang, Ho-Min Chen, Fei-Yuan Hsiao
Summary: This study is the first population-based study in Asia and provides comprehensive evidence of epidemiology, treatment patterns, and survivals of CLL/SLL in an Asian population.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
(2021)
Review
Health Care Sciences & Services
Masa Lasica, Mary Ann Anderson
Summary: Venetoclax is a highly selective BCL-2 inhibitor that has shown remarkable efficacy in CLL, AML, and MM. However, it is not curative and further research is needed to understand resistance mechanisms.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Chemistry, Multidisciplinary
Yuan-yuan Wei, Yan Ma, Song-yu Yao, Ling-hui Kong, Xiao Liu, Jing-rui Chai, Jing Chen, Wei Li, Yu-jun Wang, Li-ming Shao, Jing-gen Liu
Summary: SLL-039 and SLL-1206 are potent and long-lasting analgesic agents with antipruritic effects, showing potential as novel analgesics with fewer side effects. They activate K opioid receptors and do not cause sedation or conditioned place aversion, suggesting their promise as effective pain relief options.
ACTA PHARMACOLOGICA SINICA
(2022)
Article
Medicine, General & Internal
Paolo Ghia, Gisoo Barnes, Keri Yang, Constantine S. Tam, Tadeusz Robak, Jennifer R. Brown, Brad S. Kahl, Tian Tian, Andy Szeto, Jason C. Paik, Mazyar Shadman
Summary: During the first 24 weeks of treatment, zanubrutinib was associated with better health-related quality of life outcomes in treatment-naive CLL/SLL patients without del(17p) compared to BR.
CURRENT MEDICAL RESEARCH AND OPINION
(2023)
Article
Oncology
Sunnia T. Chen, Leylah Azali, Lindsay Rosen, Qiuhong Zhao, Tracy Wiczer, Marilly Palettas, John Gambril, Onaopepo Kola-Kehinde, Patrick Ruz, Sujay Kalathoor, Kerry Rogers, Adam Kittai, Michael Grever, Farrukh Awan, John C. Byrd, Jennifer Woyach, Seema A. Bhat, Daniel Addison
Summary: This study aimed to evaluate the association between first-generation Bruton's tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and novel selective second-generation BTKi therapy, acalabrutinib, with hypertension. The results showed that nearly half of the patients treated with acalabrutinib developed new or worsened hypertension. Furthermore, early systolic blood pressure increase was associated with an increased risk of major cardiovascular events.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Hematology
Lukas Smolej, Yvona Brychtova, Eduard Cmunt, Michael Doubek, Martin Spacek, David Belada, Martin Simkovic, Lukas Stejskal, Irena Zygulova, Renata Urbanova, Martin Brejcha, Jana Zuchnicka, Heidi Mocikova, Tomas Kozak
Summary: The study showed that low-dose FCR is a well-tolerated and effective first-line regimen for selected elderly/comorbid patients with CLL/SLL, particularly those with favorable biology. Neutropenia was a common adverse event, but serious infections were relatively low.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)